摘要
目的探讨血脂康对急性冠脉综合征(ACS)患者血浆白细胞介素-6(IL-6)及单核细胞趋化因子-1(MCP-1)的影响。方法采用酶联免疫吸附实验(ELISA)检测80例ACS患者服用血脂康前后血浆IL-6及MCP-1水平。结果 ACS组血浆IL-6、MCP-1水平为(25.45±6.34)ng/mL、(19.98±4.57)pg/L,显著高于对照组的(19.68±5.54)ng/mL和(14.45±4.35)pg/L(P<0.01),服用血脂康4周后血浆IL-6及MCP-1水平下降(P<0.01)。结论 ACS患者血浆IL-6及MCP-1水平升高与冠脉炎症反应相关,血脂康可显著降低ACS患者血浆IL-6及MCP-1水平,改善冠心病患者的预后。
Objective To investigate the effects of Xuezhikang capsules on plasma interlekin-6（IL-6） and monocyte chemotactic factor-1（MCP-1） in patients with acute coronary syndrome（ACS）.Methods The levels of IL-6 and MCP-1 were detected by enzyme linked immunosorbent assay（ELISA） and before and after oral administration of Xuezhikang capslues in 80 patients with ACS.Results The levels of IL-6 and MCP-1（25.45 ng/mL±6.34 ng/mL,19.98 pg/L±4.57 pg/L） in patients with ACS group were significantly increased compared with that in health individuals（19.68 ng/mL±5.54 ng/mL,14.45 pg/L±4.35 pg/L,P0.01）.The levels of IL-6 and MCP-1 were decreased at 4 weeks after treatment of Xuezhikang capsules（P0.01）.Conclusion The IL-6 and MCP-1 were the important factors in the prognosis in ACS.Xuezhikang capsules could decrease the levels of serum IL-6 and MCP-1 and alleviate inflammatory reaction in patients with ACS.
出处
《中西医结合心脑血管病杂志》
2012年第12期1431-1432,共2页
Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
基金
河北省医学科学研究重点课题计划基金项目(No.07150)
